Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies | ||
By: Nasdaq / GlobeNewswire - 24 Apr 2019 | Back to overview list |
|
Distribution agreement for Tru Niagen (nicotinamide riboside) in Vancouver area provides access to high-end pharmacies and clinics LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses. According to Orbis Research, the $250 billion emerging anti-aging category is expected to reach some $331 billion by the year 2021, with rapid growth fueled by advancements in science and technology, and an aging global population. In 2016, 8.5% of people worldwide were aged 65 and over, a number that is expected to jump to nearly 17% of the world’s population by the year 2050. “Given the size of the global market, and the access to a key influencer group in British Columbia, we believe this partnership is an important milestone in our global expansion strategy,” said ChromaDex CEO Rob Fried. “WELL is focused on improving healthcare and driving preventative health across Canada through technology and scale,” said Hamed Shahbazi, WELL’s Chairman and CEO. “To date, with the support of Mr. Li Ka-shing, we have already become British Columbia’s largest network of primary care clinics and one of the most significant EMR hosting providers in the province.” “Our latest launch of patient centric technology is not related to software or hardware, it is TRU NIAGEN® which clinical evidence indicates supports the healthy ageing process,” Shahbazi noted. “We are excited to introduce it to BC physicians at a conference, featuring ChromaDex Chief Scientific Advisor, Dr. Charles Brenner, on April 24th.” Tru Niagen is a breakthrough supplement clinically proven to increase your NAD (nicotinamide adenine dinucleotide) levels which stimulate cellular energy production and support cellular repair. Decreased NAD levels have been associated with many age-related declines in overall health. For additional information on the science supporting Tru Niagen visit www.truniagen.ca. About TRU NIAGEN®: About ChromaDex: Forward-Looking Statements: ChromaDex Media Contact: ChromaDex Investor Relations Contact: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |